INTRODUCTION.: There are some 30–40 genotypes of human papillomavirus (HPV) that
cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and …

Clinical trials for prophylactic human papillomavirus (HPV) vaccines have shown
overwhelmingly positive results. It is expected that with good coverage of the vaccine, 70 …

Human papilloma virus (HPV) infections, which are common, produce epithelial lesions of
the nongenital and genital skin and mucous membranes. Although most infections are …

Approximately 250,000 women die every year of cervical cancers caused by human
papillomavirus (HPV). Most of these could have been prevented by the currently available …

Human papillomavirus (HPV) infections cause several common gynecologic problems.
Oncogenic HPV infections are responsible for abnormal cervical cytology, cervical …

Genital human papillomavirus (HPV) infection and HPV‐associated cervical and other
anogenital cancers are significant public health problems. HPV 16 and HPV 18 are …

Opinion statement In the United States, there are 11,150 cases and 3670 deaths projected
due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 …

A common sexually transmitted infection, human papillomavirus (HPV) has been linked to
the development of cervical, anogenital, and head and neck cancers and genital warts.(2) …

Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …

Human papillomavirus (HPV) causes significant morbidity and mortality in women and men.
The HPV vaccine significantly reduces the incidence of anogenital cancer and genital warts …